Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EOLSNASDAQ:HCMNASDAQ:IMVTNASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOLSEvolus$9.97+8.5%$10.56$8.67▼$17.82$642.83M1.11716,714 shs1.80 million shsHCMHUTCHMED$13.60-2.1%$14.07$11.51▼$21.50$2.37B0.55100,534 shs87,988 shsIMVTImmunovant$15.41+3.8%$14.94$12.72▼$34.47$2.62B0.751.19 million shs1.01 million shsMLTXMoonLake Immunotherapeutics$41.16+5.5%$38.34$31.42▼$58.26$2.63B1.31350,198 shs493,778 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOLSEvolus+6.40%+3.00%-17.47%-30.52%-22.89%HCMHUTCHMED-1.23%+1.49%-9.33%-15.48%-26.61%IMVTImmunovant+3.63%+6.57%-2.47%-16.66%-39.31%MLTXMoonLake Immunotherapeutics+5.38%+5.73%-2.74%+2.13%+1.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEOLSEvolus3.6751 of 5 stars3.50.00.03.52.82.50.6HCMHUTCHMED2.019 of 5 stars3.02.00.00.02.20.01.9IMVTImmunovant1.502 of 5 stars3.50.00.00.02.91.70.0MLTXMoonLake Immunotherapeutics1.967 of 5 stars3.51.00.00.02.82.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEOLSEvolus 3.00Buy$23.75138.21% UpsideHCMHUTCHMED 2.00Hold$19.0039.71% UpsideIMVTImmunovant 2.90Moderate Buy$38.33148.76% UpsideMLTXMoonLake Immunotherapeutics 3.00Buy$78.7191.24% UpsideCurrent Analyst Ratings BreakdownLatest EOLS, MLTX, IMVT, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025MLTXMoonLake ImmunotherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$61.005/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/13/2025MLTXMoonLake ImmunotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$78.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.005/8/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/30/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.004/17/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/10/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.004/9/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/20/2025IMVTImmunovantGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEOLSEvolus$275.46M2.33N/AN/A($0.36) per share-27.69HCMHUTCHMED$630.20M3.76$0.55 per share24.51$4.27 per share3.19IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$8.15 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEOLSEvolus-$61.69M-$0.89N/AN/AN/A-22.33%-847.60%-22.15%7/30/2025 (Estimated)HCMHUTCHMED$100.78MN/A0.009.32N/AN/AN/AN/A6/18/2025 (Estimated)IMVTImmunovant-$259.34M-$2.62N/AN/AN/AN/A-77.94%-69.82%6/4/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$36.01M-$2.30N/AN/AN/AN/A-15.54%-15.09%8/6/2025 (Estimated)Latest EOLS, MLTX, IMVT, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEOLSEvolusN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEOLSEvolus20.582.472.23HCMHUTCHMED0.072.812.68IMVTImmunovantN/A6.046.04MLTXMoonLake ImmunotherapeuticsN/A25.5125.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEOLSEvolus90.69%HCMHUTCHMED8.82%IMVTImmunovant47.08%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipEOLSEvolus5.90%HCMHUTCHMED3.60%IMVTImmunovant5.90%MLTXMoonLake Immunotherapeutics12.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEOLSEvolus17064.48 million59.46 millionOptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableIMVTImmunovant120169.86 million159.84 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.22 millionOptionableEOLS, MLTX, IMVT, and HCM HeadlinesRecent News About These CompaniesMoonLake Immunotherapeutics stock surges on FT report of Merck buyout talksJune 2 at 5:42 PM | investing.comMerck held talks to buy biotech MoonLake for over $3 billion, FT reportsJune 2 at 5:08 PM | reuters.comBank of America Corp DE Sells 76,559 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)June 2 at 3:33 AM | marketbeat.comNorthern Trust Corp Has $772,000 Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 31 at 3:01 AM | marketbeat.comEquities Analysts Set Expectations for MLTX Q2 EarningsMay 31 at 1:31 AM | americanbankingnews.comHC Wainwright Has Optimistic Outlook of MLTX Q2 EarningsMay 30, 2025 | marketbeat.comH.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PTMay 29, 2025 | finance.yahoo.comH.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PTMay 27, 2025 | insidermonkey.comBNP Paribas Financial Markets Takes $413,000 Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 27, 2025 | marketbeat.comWoodline Partners LP Grows Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 24, 2025 | marketbeat.comNuveen Asset Management LLC Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 24, 2025 | marketbeat.comPoint72 Asset Management L.P. Invests $5.35 Million in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 22, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded by Wolfe Research to Outperform RatingMay 21, 2025 | marketbeat.comWexford Capital LP Purchases 10,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)May 21, 2025 | marketbeat.comAmeriprise Financial Inc. Increases Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 21, 2025 | marketbeat.comWolfe Research Upgrades MoonLake Immunotherapeutics (MLTX)May 20, 2025 | msn.comWolfe Research Upgrades MoonLake Immunotherapeutics (MLTX) with a Bullish Outlook | MLTX Stock NewsMay 19, 2025 | gurufocus.comEnsign Peak Advisors Inc Sells 33,174 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)May 19, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 19, 2025 | marketbeat.comPolar Capital Holdings Plc Raises Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 17, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEOLS, MLTX, IMVT, and HCM Company DescriptionsEvolus NASDAQ:EOLS$9.97 +0.78 (+8.49%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$10.04 +0.06 (+0.65%) As of 04:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.HUTCHMED NASDAQ:HCM$13.60 -0.29 (-2.09%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$14.39 +0.79 (+5.81%) As of 04:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Immunovant NASDAQ:IMVT$15.41 +0.56 (+3.77%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$15.28 -0.14 (-0.88%) As of 04:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.MoonLake Immunotherapeutics NASDAQ:MLTX$41.16 +2.15 (+5.51%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$50.40 +9.24 (+22.44%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern 3 Stocks With 3% to 9% Yields Just Raised Dividends Again MarketBeat Week in Review – 05/26 - 05/30 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
